Ferring Pharmaceuticals is an R&D-driven biotechnology company, headquartered in St. Prex, Switzerland. Founded in 1950, Ferring has branches in nearly 60 countries, and its products have been sold in 110 countries worldwide. As the leading company in the field of Reproductive Health and Women's Health, Ferring has always been paying close attention to the reproductive healthcare demand in China and the world. In this regard, Ferring has been steadily increasing its R&D investments for reproductive diseases, and actively seeking medical solutions that are both innovative and personalized. Guided by its strategic insights into innovative R&D, Ferring is fully committed to the support of early basic research and strives to promote the translation of basic research findings into the clinic. Ferring hopes to make innovative biomedical R&D available to patients as soon as possible, and lead the charge into the frontiers of reproductive medicine.

The Institute for Stem Cells and Regeneration (ISCR), Chinese Academy of Sciences (CAS), is an institute that specializes in stem cell research and regenerative medicine, and which synergistically integrates the core strengths and unique platform technologies of the relevant CAS institutes. The SRLab (State Key Laboratory of Stem Cells and Reproductive Biology) is the cornerstone department of the ISCR, possessing a strong cadre of research scientists who have made remarkable achievements in the field of reproductive biology. As the foundation of the ISCR, the SRLab has been attracting various national and international resources to build a world-class center for basic and translational R&D. Under the umbrella of the ISCR, the SRLab is actively exploring new models of collaboration between government-sponsored R&D institutions, industry R&D, and global corporations, to spearhead the integration between academic research and translational R&D, and lead the charge in building an innovation-driven ecosystem.

Objectives:

Ferring Pharmaceuticals and the ISCR, CAS, have established a strategic collaboration agreement to work closely together on both basic research and translational R&D. Both sides have come together to jointly establish the Ferring Institute of Reproductive Medicine (FIRM), to promote the clinical translation of cutting edge biomedical research, and provide solutions for the prevention, diagnosis, and treatment of reproductive diseases.

Project research areas (Research Scope):

• Placenta Biology
• Uterine Biology and Infertility/Pathologies
• Gametogenesis and Male/Female Infertility
• New Technologies and Future Applications – Next Generation ART